Liquid biopsy employs the analyses of circulating cell-free DNA (ctDNA). ctDNA can be found in the plasma, and it provides a non-invasive approach in the assessment of metastatic melanoma. Moreover, it allows for real-time monitoring of progression or response to therapies.
ctDNA is a promising predictive biomarker, that has the potential to transform the field diagnostics for patients with melanoma.
Thank you for watching!